Li-Yen Wong

Li-Yen Wong, PhD


Focus areas

Gene therapy, cardiac reprogramming, stem cell culture, maintenance and differentiation, molecular cloning


Li-Yen Wong, PhD
Maastricht UMC+
Clinical Genetics
PO box 5800
6202 AZ Maastricht
T: (+31) (0)43 3881303

Curriculum vitae

Li-Yen Wong is a postdoctoral researcher at the department of Genetics and Cell Biology. She graduated from the University of Melbourne, Australia with a Bachelor’s degree in Biomedical Engineering (hons) specializing in tissue engineering and regenerative medicine. Her PhD was completed at the Australian Institute for Bioengineering and Nanotechnology, the University of Queensland (Australia) and was focused on targeted gene therapy. Her research project was based on using targeted nanoparticles to directly reprogram cardiac fibroblasts into cardiomyocytes by delivering cardiac-specific genes (via plasmids or miRNA). During her PhD she was also involved in in vivo studies using mice and rats, where she was investigating the targeted delivery of genes (tagged with a fluorophore) to the heart after inducing a myocardial infarct.

After graduating from her PhD, she started working as a postdoc at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), an independent Australian federal government agency that funds scientific research. She was heavily involved in various projects, particularly the generation of reporter cell lines, molecular cloning and high-throughput screening using a robotic system. This work produced a multitude of various reporters using HES/IPS, MSCs and immortalized cell lines for different lineages (adipogenic, myogenic and osteogenic) with lentiviral and CRISPR/Cas9 technologies.

In the lab of prof Jan Glatz and prof Han Brunner Li-Yen Wong is working closely with Florence van Tienen, PhD on the generation of iPSC-derived cardiomyocytes from patients with dilated cardiomyopathies into a functional model for testing pathogenicity of gene variants. The research project is to ultimately develop therapies that can be used on patients with genetic cardiomyopathies, by using CRISPR-CAS genetic modification.

Social media